Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).
CommSec's Tom Piotrowski speaks with Novogen Ltd (NRT) CEO & Executive Director, Dr James Garner about the company’s key milestones over the past 12 months and the clinical trials for its brain cancer treatment drug.
Novogen (ASX: NRT), Chief Executive Officer & Executive Director Dr James Garner , gives an update on Novogen since coming on board in 2016.
CommSec's Tom Piotrowski speaks with Kazia Therapeutics (KZA) CEO & Managing Director, Dr James Garner about the company’s recent name change from Novogen and progress of its ovarian cancer and brain cancer drug trials.
Novogen Sky News Interview
Kazia Therapeutics Limited
Three International Towers
Level 24, 300 Barangaroo Avenue
Sydney NSW 2000, Australia
Which of the following group do you best fit?
Subscribe to our Email Alerts